Regen Therapeutics is a small Pharmaceutical from the UK
with a market cap of only £6m
by 2006 they expect colostrinin to be on sale in the USA
you can visit the web site at
regentherapeutics.com
look forward to any comments and feed back
The principal activity of ReGen Therapeutics’ pharmaceutical business is the research and development of Colostrinin™ and its constituent peptides as a treatment for Alzheimer's disease and other neurological disorders. Colostrinin™ is a proline-rich polypeptide complex derived from ovine and bovine colostrum. Colostrum is the mammal's first milk after the birth of an offspring.
ReGen’s strategy is to develop a pharmaceutical preparation, based on the peptides contained within the Colostrinin™ complex, which has already shown efficacy when tested on human subjects suffering from Alzheimer’s disease. The results of research announced in April 2005 have indicated that Colostrinin™ and one of its constituent peptides may also have applications in the treatment of Parkinson’s disease.
A nutraceutical version of Colostrinin™ for use in the early stages of cognitive decline, a product primarily targeted at humans, is in an advanced stage of development. Discussions with potential development partners are ongoing. We are also some way forward in developing Colostrinin™ as a veterinary nutraceutical for companion animals. |
